TLR9-Fc Plasmid Expression for Bioavailability and Homeostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies fail to effectively regulate the production of bioactive molecules such as toll-like receptors and enzymes, leading to homeostasis disruption and associated diseases.
Innovation Solution
The use of recombinant plasmids encoding nucleotide sequences that upregulate the production of mRNA for fusion proteins like TLR3-Fc, TLR9-Fc, DNAse I-Fc, NGF-Fc, and insulin-Fc, administered via vectors like adeno-associated virus (AAV) to increase endogenous production in target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to regulate bioactive molecules, then treatment is provided, but they fail to effectively regulate production leading to homeostasis disruption
Solution Approach 1:
The patent uses adeno-associated virus (AAV) as an intermediary vector to deliver the TLR9-Fc fusion protein gene to target cells. This viral vector mediates the transfer of genetic material, enabling effective regulation of bioactive molecule production that existing therapies cannot achieve alone.
Solution Approach 2:
The invention changes the fundamental parameter of protein production by introducing a fusion protein construct (TLR9-Fc) with modified properties. The fusion of TLR9 with the Fc fragment of IgG creates a molecule with altered stability, half-life, and cellular interaction characteristics, enabling effective homeostasis regulation.
2Quantity of substance
If fusion proteins like TLR9-Fc are produced, then bioavailability increases, but complex plasmid construction and viral vector administration are required
Solution Approach 1:
The patent merges multiple functional elements into a single plasmid construct: the TLR9 coding sequence, the Fc fragment sequence, appropriate promoters, and regulatory elements are all combined in one recombinant plasmid. This integrated approach simplifies the overall system while achieving the desired bioavailability enhancement.
Solution Approach 2:
The adeno-associated virus vector serves multiple functions: it delivers the genetic material, enables transcription of the fusion protein gene, and facilitates expression in target cells. This multi-functional vector system achieves high bioavailability without requiring multiple separate components.
3Stability of the object's composition
If homeostasis is maintained through proper bioactive molecule levels, then disease prevention occurs, but existing therapies cannot achieve effective regulation
Solution Approach 1:
The TLR9-Fc fusion protein acts as a regulatory molecule that responds to cellular conditions and modulates immune responses accordingly. By expressing this fusion protein through the AAV-delivered plasmid, the system creates a feedback mechanism that helps maintain homeostasis by regulating bioactive molecule levels in response to physiological needs.
Data Source
AI summary
Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.